GPR40 受体苯丙酸类激动剂三维定量构效关系研究

苯丙酸类化合物是G蛋白偶联受体40(GPR40)潜在的生物活性药物。本文基于比较分子力场分析法(Co MFA)和比较分子相似性指数分析法(CoMSIA),分别建立了40个已知活性的GPR40受体苯丙酸类激动剂的三维定量构效关系(3D-QSAR)模型,研究该类激动剂与生物活性之间的关系。CoMFA和CoMSIA模型的交叉验证系数(q~2)分别为0. 527和0. 500,拟合验证系数(r~2)分别为0. 901和0. 860,两个3D-QSAR模型预测值与实验值基本一致,表明模型具有良好的可信度和预测能力。根据两个3D-QSAR模型提供的立体场、静电场、疏水场、氢键供体场和氢键受体场所提供的信息提出优化该类抑制剂结构的药物设计思路,为指导设计更高活性的GPR40激动剂以及GRR40新分子激动活性的预测提供理论依据。     

One-pot approach for the synthesis of trans-cyclopropyl compounds from aldehydes. Application to the synthesis of GPR40 receptor agonists

A novel multicatalytic one-pot process providing trans-cyclopropyl compounds from corresponding aldehydes has been developed and applied to the synthesis of GPR40 small molecule agonists.     

Evaluation of blue and green absorbing proteorhodopsins as holographic materials

Transient holographic diffraction is observed for the green (GPR) and blue (BPR) absorbing proteorhodopsins (BAC31A8 and HOT75M1, respectively), as well as the GPR E108Q and BPR E110Q variants. In contrast to bacteriorhodopsin, where the metastable bR-M pair is responsible for generating diffraction, the pR and red-shifted N-like states fulfill that role in both the green and blue wild-type proteorhodopsins. The GPR E108Q and BPR E110Q variants, however, behave more similarly to their bacteriorhodopsin analogue, D96N, with diffraction arising from the PR M-state (strongly enhanced in both GPR E108Q and BPR E110Q). Of the four proteins evaluated, wild type (WT) GPR and GPR E108Q produce the highest diffraction efficiencies, etamax, at approximately 1% for a 1.7 OD sample. GPR E108Q, however, requires 1-2 orders of magnitude less laser intensity to generate eta equivalent to WT GPR and BR D96N under similar conditions (as compared to literature values). WT BPR requires lower actinic powers than GPR but diffracts only about 30% as well. BPR E110Q performs the most poorly of the four, with etamax < 0.05% for a 1.4 OD film. The Kramers-Kronig transformation and Koglenik's coupled wave theory were used to predict the dispersion spectra and diffraction efficiency for the long M-state variants. To a first approximation, the gratings formed by all samples decay upon discontinuing the 520 nm actinic beams with a time constant characteristic of the appropriate intermediate: the N-like state for WT GPR and BPR and the M-state for GPR 108Q and BPR E110Q.     

Raman spectroscopy reveals direct chromophore interactions in the Leu/Gln105 spectral tuning switch of proteorhodopsins

Proteorhodopsins are an extensive family of photoactive membrane proteins found in proteobacteria distributed throughout the world's oceans which are often classified as green- or blue-absorbing (GPR and BPR, respectively) on the basis of their visible absorption maxima. GPR and BPR have significantly different properties including photocycle lifetimes and wavelength dependence on pH. Previous studies revealed that these different properties are correlated with a single residue, Leu105 in GPR and Gln105 in BPR, although the molecular basis for the different properties of GPR and BPR has not yet been elucidated. We have studied the unexcited states of GPR and BPR using resonance Raman spectroscopy which enhances almost exclusively chromophore vibrations. We find that both spectra are remarkably similar, indicating that the retinylidene structure of GPR and BPR are almost identical. However, the frequency of a band assigned to the retinal C13-methyl-rock vibration is shifted from 1006 cm (-1) in GPR to 1012 cm (-1) in BPR. A similar shift is observed in the GPR mutant L105Q indicating Leu and Gln residues interact differently with the retinal C13-methyl group. The environment of the Schiff base of GPR and BPR differ as indicated by differences in the H/D induced down-shift of the Schiff base vibration. Residues located in transmembrane helices (D-G) do not contribute to the observed differences in the protein-chromophore interaction between BPR and GPR based on the Raman spectra of chimeras. These results support a model whereby the substitution of the hydrophilic Gln105 in BPR with the smaller hydrophobic Leu105 in GPR directly alters the environment of both the retinal C13 group and the Schiff base.     

新型GPR40激动剂的合成及其生物活性

以丁炔二醇为起始原料,用叔丁基二甲基氯硅烷进行单保护后,与2-(6-羟基-2,3-二氢苯并呋喃)乙酸甲酯经Mitsunobu反应制得2-{6-［4-(叔丁基二甲硅烷氧基)丁-2炔基氧基］-2,3-二氢苯并呋喃}乙酸甲酯(3); 3脱除保护后与苯酚衍生物发生Mitsunobu反应,随后经水解合成了6个结构新颖的苯并二氢呋喃衍生物(7a~7f),其结构经¹H NMR, ¹³C NMR和HR-EI-MS表征。GPR40激动活性测试结果表明：7a~7f对GPR40均有激动作用,其中7e和7f激动活性最强,EC₅₀分别为0.593 μmol·L^-1和0.596 μmol·L^-1。     

Feasible Synthesis of Antagonist of GPR40 by Constructing 2-Thiouracil Ring viaAcid Mediated Cyclization

GW1100 is an antagonist of GPR40 identified by high throughput screening recently. The synthesis of GW1100 has been developed. The key step involves cyclization of the 2-thiouracil heterocycle under acidic condition at room temperature.     

G-蛋白偶联受体GPR120分子模建研究

新的长链脂肪酸受体G-蛋白偶联受体120 (G-protein-coupled receptor120, GPR120)是2型糖尿病的潜在治疗靶标. 由于其晶体结构迄今尚未获得, 成为基于结构的新药设计的瓶颈. 首先, 以人体β2肾上腺能素受体(human β2 adrenergic receptor, β2AR)晶体结构为模板, 通过同源模建方法构建GPR120三维结构, 对整个体系进行包膜的分子动力学模拟. 然后采用分子对接技术模建了GPR120的小分子激动剂GW9508与GPR120的相互作用模型, 发现了受体分子识别的关键性残基, 为开展定点突变实验提供了指导意义. 所建模型为研究受体与配体作用提供了合理的初始结构, 此方法也适用于其他G蛋白偶联受体的分子模建.     

Asymmetric syntheses of a GPR40 receptor agonist via diastereoselective and enantioselective conjugate alkynylation

Two asymmetric methods to synthesize a potent GPR40 receptor agonist are reported. Both synthetic routes utilize readily available, inexpensive starting materials and reagents. The first route relies on a highly diastereoselective conjugate alkynylation of an ephedrine-derived oxazepanedione acceptor. The second route features the enantioselective alkynylation of a Meldrum’s acid-derived acceptor mediated by a chiral zinc cinchonidine reagent.     

In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases

GPR17, a previously orphan receptor responding to both uracil nucleotides and cysteinyl-leukotrienes, has been proposed as a novel promising target for human neurodegenerative diseases. Here, in order to specifically identify novel potent ligands of GPR17, we first modeled in silico the receptor by using a multiple template approach, in which extracellular loops of the receptor, quite complex to treat, were modeled making reference to the most similar parts of all the class-A GPCRs crystallized so far. A high-throughput virtual screening exploration of GPR17 binding site with more than 130,000 lead-like compounds was then applied, followed by the wet functional and pharmacological validation of the top-scoring chemical structures. This approach revealed successful for the proposed aim, and allowed us to identify five agonists or partial agonists with very diverse chemical structure. None of these compounds could have been expected ‘a priori’ to act on a GPCR, and all of them behaved as much more potent ligands than GPR17 endogenous activators.     

Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes

GPR120 is a promising target for the treatment of type 2 diabetes (T2DM), which is activated by free fatty acids (FFAs) and stimulates the release of glucagon-like peptide-1(GLP-1). GLP-1, as an incretin, can enhance glucose-dependent secretion of insulin from pancreatic beta cells and reduce blood glucose. In this study, a series of novel GPR120 agonists were designed and synthesized to improve the stability and hydrophilicity of the phenylpropanoic acid GPR120 agonist TUG-891. Compound 11b showed excellent GPR120 agonistic activity and pharmacokinetic properties, and could reduce the blood glucose of normal mice in a dose-dependent manner. In addition, no hypoglycemic side effects were observed even at a dose of 100 mg/kg. Moreover, 11b showed good anti-hyperglycemic effects in diet-induced obese (DIO) mice. Molecular simulation illustrated that compound 11b could enter the active site of GPR120 and interact with ARG99. Taken together, the results indicate that compound 11b might be a promising drug candidate for the treatment of T2DM.     

A categorical structure–activity relationship analysis of GPR119 ligands

The categorical structure–activity relationship (cat-SAR) expert system has been successfully used in the analysis of chemical compounds that cause toxicity. Herein we describe the use of this fragment-based approach to model ligands for the G protein-coupled receptor 119 (GPR119). Using compounds that are known GPR119 agonists and compounds that we have confirmed experimentally that are not GPR119 agonists, four distinct cat-SAR models were developed. Using a leave-one-out validation routine, the best GPR119 model had an overall concordance of 99%, a sensitivity of 99%, and a specificity of 100%. Our findings from the in-depth fragment analysis of several known GPR119 agonists were consistent with previously reported GPR119 structure–activity relationship (SAR) analyses. Overall, while our results indicate that we have developed a highly predictive cat-SAR model that can be potentially used to rapidly screen for prospective GPR119 ligands, the applicability domain must be taken into consideration. Moreover, our study demonstrates for the first time that the cat-SAR expert system can be used to model G protein-coupled receptor ligands, many of which are important therapeutic agents.     

Enantioselective synthesis of a GPR40 agonist AMG 837 via catalytic asymmetric conjugate addition of terminal alkyne to α,β-unsaturated thioamide

A concise enantioselective synthetic route to a potent GPR40 agonist AMG 837 is described. The crucial catalytic asymmetric conjugate addition of terminal alkyne was promoted by a soft Lewis acid/hard Br?nsted base cooperative catalyst, allowing efficient construction of the requisite stereogenic center. The thioamide functional group is key to both activation in asymmetric alkynylation and facile transformation into carboxylic acid.     

Parameterization of the GPR119 Receptor Agonist AR231453

The GPR119 receptor is a class A G protein‐coupled receptor expressed mainly in pancreatic beta cells. Since GPR119 receptor activation ameliorates Type 2 Diabetes through an increase in glucose‐dependent insulin release, the development of new GPR119 receptor agonists would be worthwhile. A better understanding of the way agonists interact with the receptor would help to design better ligands for the receptor. It also would help to better understand the agonist mechanism of action. An understanding of how agonists interact with the receptor can be acquired using molecular dynamics simulations, which cannot be performed without having force field parameters for the ligand molecule. This study presents the development of CHARMM force field parameters for AR231453, the prototypical first potent and orally available GPR119 agonist, using the Force Field Tool Kit. The parameters are validated through Normal Mode Analysis calculations and molecular dynamics simulations in combination with infrared spectroscopy. © 2017 Wiley Periodicals, Inc.     

Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis

Cannabinoids act as pleiotropic compounds exerting, among others, a broad-spectrum of neuroprotective effects. These effects have been investigated in the last years in different preclinical models of neurodegeneration, with the cannabinoid type-1 (CB₁) and type-2 (CB₂) receptors concentrating an important part of this research. However, the issue has also been extended to additional targets that are also active for cannabinoids, such as the orphan G-protein receptor 55 (GPR55). In the present study, we investigated the neuroprotective potential of VCE-006.1, a chromenopyrazole derivative with biased orthosteric and positive allosteric modulator activity at GPR55, in murine models of two neurodegenerative diseases. First, we proved that VCE-006.1 alone could induce ERK1/2 activation and calcium mobilization, as well as increase cAMP response but only in the presence of lysophosphatidyl inositol. Next, we investigated this compound administered chronically in two neurotoxin-based models of Parkinson’s disease (PD), as well as in some cell-based models. VCE-006.1 was active in reversing the motor defects caused by 6-hydroxydopamine (6-OHDA) in the pole and the cylinder rearing tests, as well as the losses in tyrosine hydroxylase-containing neurons and the elevated glial reactivity detected in the substantia nigra. Similar cytoprotective effects were found in vitro in SH-SY5Y cells exposed to 6-OHDA. We also investigated VCE-006.1 in LPS-lesioned mice with similar beneficial effects, except against glial reactivity and associated inflammatory events, which remained unaltered, a fact confirmed in BV2 cells treated with LPS and VCE-006.1. We also analyzed GPR55 in these in vivo models with no changes in its gene expression, although GPR55 was down-regulated in BV2 cells treated with LPS, which may explain the lack of efficacy of VCE-006.1 in such an assay. Furthermore, we investigated VCE-006.1 in two genetic models of amyotrophic lateral sclerosis (ALS), mutant SOD1, or TDP-43 transgenic mice. Neither the neurological decline nor the deteriorated rotarod performance were prevented with this compound, and the same happened with the elevated microglial and astroglial reactivities, albeit modest spinal motor neuron preservation was achieved in both models. We also analyzed GPR55 in these in vivo models and found no changes in both TDP-43 transgenic and mSOD1 mice. Therefore, our findings support the view that targeting the GPR55 may afford neuroprotection in experimental PD, but not in ALS, thus stressing the specificities for the development of cannabinoid-based therapies in the different neurodegenerative disorders.     

超临界相由合成气合成低碳醇的研究

选择有代表性的Ｃｕ－Ｃｏ,Ｚｎ－Ｃｒ和ＺＲ－Ｍｎ体系为催化剂,研究了超临界条件下由合成气 民低碳醇的规律及提高产物中Ｃ２＋ＯＨ含量的可能性。结果表明,三种催化剂上超临界相合成醇反应的ＣＯ转化率都比气相合成醇反应的高。Ｃｕ－Ｃｏ催化剂上超临界相合成反应的醇选择性低于气相合成者,但合成醇的产物与气相合成的相同,且均符合Ｓｃｈｕｌｚ－Ｆｌｏｒｙ分布。Ｚｎ－Ｃｒ和Ｚｒ－Ｍｎ催化剂上的产物分布不符合Ｓｃｈｕ     

Biogas Production from Anaerobic Co-digestion of Food Waste with Dairy Manure in a Two-Phase Digestion System

Co-digestion of food waste and dairy manure in a two-phase digestion system was conducted in laboratory scale. Four influents of R0, R1, R2, and R3 were tested, which were made by mixing food waste with dairy manure at different ratios of 0:1, 1:1, 3:1, and 6:1, respectively. For each influent, three runs of experiments were performed with the same overall hydraulic retention time (HRT) of 13 days but different HRT for acidification (1, 2, and 3 days) and methanogenesis (12, 11, and 10 days) in two-phase digesters. The results showed that the gas production rate (GPR) of co-digestion of food waste with dairy manure was enhanced by 0.8–5.5 times as compared to the digestion with dairy manure alone. Appropriate HRT for acidification was mainly determined by the biodegradability of the substrate digested. Three-, 2-, and 1-day HRT for acidification were found to be optimal for the digestion of R0, R1, and R2/R3, respectively, when overall HRT of 13 days was used. The highest GPR of 3.97 L/L·day was achieved for R3(6:1) in Run 1 (1 + 12 days), therefore, the mixing ratio of 6:1 and HRT of 1 day for acidification were considered to be the optimal ones and thus recommended for co-digestion of food waste and dairy manure. There were close correlations between degradation of organic matters and GPR. The highest VS removal rate was achieved at the same HRT for acidification and mixing ratio of food waste and dairy manure as GPR in the co-digestion. The two-phase digestion system showed good stability, which was mainly attributed to the strong buffering capacity with two-phase system and the high alkalinity from dairy manure when co-digested with food waste.     

GPR52——治疗神经系统疾病的新靶点

GPR52是G蛋白偶联受体家族的一员,它的内源性配体至今仍未发现.但其在大脑纹状体中高度表达,能够抑制多巴胺D2受体并通过促进神经细胞中cAMP的积累激活多巴胺D1受体和NMDA受体,成为治疗精神分裂症的潜在靶点.同时GPR52受体反向激动剂被证明不仅可以降低mHTT的水平而且能够治疗小鼠模型中的亨廷顿病相关症状.     

Novel and accurate mathematical simulation of various models for accurate prediction of surface tension parameters through ionic liquids

Ionic Liquids (ILs) as a novel class of liquid solvent simultaneously carry the positive characteristics of both molten salts and organic liquids. Remarkable positive properties of ILs have such as low vapor pressure and excellent permittivity have encouraged the motivation of researchers to use them in various applications over the last decade. Surface tension is an important physicochemical property of ILs, which its experimental-based measurement has been done by various researchers. Despite great precision, some major shortcomings such as high cost and health-related problems caused the researchers to develop mathematical models based on artificial intelligence (AI) approach to predict surface tension theoretically. In this research, the surface tension of two novel ILs (bis [(trifluoromethyl) sulfonyl] imide and 1,3-nonylimidazolium bis [(trifluoromethyl) sulfonyl] imide) were predicted using three predictive models. The available dataset contains 45 input features, which is relatively high in dimension. We decided to use AdaBoost with different base models, including Gaussian Process Regression (GPR), support vector regression (SVR), and decision tree (DT). Also, for feature selection and hyper-parameter tuning, a genetic algorithm (GA) search is used. The final R²-score for boosted DT, boosted GPR, and boosted SVR is 0.849, 0.981, and 0.944, respectively. Also, with the MAPE metric, boosted GPR has an error rate of 1.73E-02, boosted SVR has an error rate of 2.35E-02, and it is 3.36E-02 for boosted DT. So, the ADABOOST-GPR model was considered as the primary model for the research.     

Synthesis and Pharmacological Profile of a New Selective G Protein-Coupled Receptor 119 Agonist; 6-((2-Fluoro-3-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)propyl)amino)-2,3-dihydro-1H-inden-1-one

6-((2-Fluoro-3-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)propyl)amino)-2,3-dihydro-1H-inden-1-one is a potent drug-like G protein-coupled receptor 119 (GPR119) agonist. It is hoped that this compound would be instrumental in probing the pharmacological potential of GPR119 agonists.     

Linkage effects on binding affinity and activation of GPR30 and estrogen receptors ERalpha/beta with tridentate pyridin-2-yl hydrazine tricarbonyl-Re/(99m)Tc(I) chelates

We describe a new structural class of neutral tridentate pyridin-2-yl hydrazine chelates for labeling with tricarbonyl Re/99mTc(I) under aqueous conditions and investigate the receptor binding of synthetic estradiol derivatives with the novel G-protein-coupled receptor GPR30 and estrogen receptors ERalpha/beta. The steroid linkage affected the affinity and selectivity of estrogen binding with these receptors. Fluorescence assays based on calcium signaling demonstrate that membrane-permeable chelates 2 and 3 interact with the receptors in whole cells. These results suggest that in vitro assays will facilitate the development of targeted imaging agents for intracellular receptors and the feasibility of targeting GPR30 and ERalpha/beta for diagnostic tumor imaging.